Amylyx Pharmaceuticals Inc (AMLX)

$AMLX TD Cowen reiterates Buy

$AMLX look at mr d_risk 👇 junk!

$AMLX - Amylyx Pharmaceuticals Inc. Common Stock - 10Q - Updated Risk Factors AMLX’s 10-Q reveals heightened risks from reliance on third parties, key personnel losses, halted ALS product sales, ongoing R&D expenses, expanded IP and commercialization challenges, macroeconomic and geopolitical uncertainties, and loss of emerging growth company status increasing compliance burdens. #Pharmaceuticals #RegulatoryCompliance #IntellectualProperty #ThirdPartyRisk #ALSResearch 🟢 Added 🟠 Removed https://d-risk.ai/AMLX/10-Q/2025-08-07

"Heads up alert! Upcoming earnings on Thursday, 8/7/2025 for $AMLX Bullish (7.2) --- As a leading contender in the biotechnology sector, Amylyx Pharmaceuticals (NASDAQ: AMLX) has demonstrated significant progress in its clinical pipeline, particularly with the promising developments surrounding Avexitide for post-bariatric hypoglycemia (PBH). The recent exploratory analyses from Phase 2 and 2b trials showcase Avexitide's continuous pharmacologic activity, bolstering confidence in its therapeutic potential. Furthermore, the FDA's Fast Track designation for AMX0114, a novel treatment for ALS, underscores the innovative strength within Amylyx's portfolio. Financially, while specific P/E ratios and EPS growth figures are not provided here, the company's strategic advancements position it well relative to its peers, typically characterized by high R&D expenses and investment in late-stage trials. Such R&D endeavors often lead to substantial revenue growth upon successful drug commercialization, aligning with industry trends of robust valuation metrics for companies with strong pipelines. Amylyx's focus on niche yet impactful therapeutic areas could provide significant upside potential compared to broader industry averages. --- Upcoming Earnings Report Amylyx Pharmaceuticals is set to announce its second-quarter 2025 financial results on August 7, 2025. Historically, the company has seen fluctuations in its earnings due to the developmental nature of its pipeline and the associated R&D expenditures. Analyst consensus is cautiously optimistic, anticipating a narrowed net loss compared to previous quarters, reflecting the company's strategic cost management and milestone achievements. The market will closely watch revenue forecasts, particularly any updates regarding licensing agreements or potential partnership deals that could impact financial performance. An emphasis on forward guidance related to Avexitide and AMX0114 could significantly influence investor sentiment. --- Sector Performance The biotechnology sector, to which Amylyx belongs, has experienced a dynamic year marked by increased regulatory approvals and a surge in high-profile mergers and acquisitions. The sector's growth is driven by innovation in gene therapies, personalized medicine, and targeted therapeutics, with companies focusing on rare and complex diseases seeing heightened investor interest. Despite economic headwinds, the sector's resilience is evident, with a steady influx of venture capital and strategic partnerships propelling research and development efforts. Amylyx's advancements align well with these broader sector trends, positioning it to capitalize on emerging opportunities within an evolving healthcare landscape. - Funds were net buyers of $AMLX during the previous reporting quarter. - Funds with large holdings in $AMLX include: - Perceptive Advisors LLC, MV: $28MM. Fund Rank: 61% www.perceptivelife.com - Adage Capital P, MV: $20MM. New position. Fund Rank: 86% www.adagecapital.com - Nantahala Capital Management LLC, MV: $10MM. Fund Rank: 67% www.nantahalapartners.com - Saturn V Capital, MV: $9MM. Fund Rank: 82% www.saturnfive.com - Great Point Partners LLC, MV: $6MM. New position. Fund Rank: 57% www.gppfunds.com - Last 10 days performance: 2% - Last 30 days performance: 22% - Last 90 days performance: 51% Some of the latest news articles: - Title: Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 Publication Date: 7/31/2025 1:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/amylyx-pharmaceuticals-report-second-quarter-130000937.html?.tsrc=rss - Title: Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion Publication Date: 7/15/2025 12:58:49 PM, Source: yahoo URL: https://finance.yahoo.com/news/amylyx-pharmaceuticals-shares-promising-avexitide-125849996.html?.tsrc=rss - Title: Amylyx presents new exploratory analyses from avexitide trials for PBH Publication Date: 7/14/2025 3:52:07 PM, Source: yahoo URL: https://www.clinicaltrialsarena.com/news/amylyx-avexitide-trials/?.tsrc=rss - Title: Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 Publication Date: 7/13/2025 9:00:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/amylyx-pharmaceuticals-presents-exploratory-analyses-210000455.html?.tsrc=rss Follow us on stocktwits.com. Not a financial advice. Not a trading signal."

$AMLX Trump tweet aimed at Novo Nordisk, Astrazeneca,... on MFN drug pricing will increase the odds that these companies will acquire US pharma and biotechs in the orphan drug space, aiming to reduce such geopolitical risks.

$AMLX short covering continues: since july 14th 1.5 mln shares covered. current short 2 mln. do the shorts sense something 😀

$AMLX imho NovoNordisk will be making acquisition to reinforce their drugs offerings. Novo specialised in diabetes care has no glp-1 antagonist (in fact, others don't have that either), but Novo is more pressured to make acquisitions with the sales of wegovy losing steam. In an acquisition scenario before avexitide phase 3 data release, we could be looking at 17usd-20usd , post release we could see as high as 40 usd.

$AMLX $10 still on the menu by end of the year

$AMLX tick tock PSP interim data 🚀🚀 It’s going to be earth shattering good